{"id":390542,"date":"2018-11-23T00:00:00","date_gmt":"2018-11-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0002-2018-biopharma-dyslipidemia-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-04-25T11:37:21","modified_gmt":"2026-04-25T11:37:21","slug":"dlsfmd0002-2018-biopharma-dyslipidemia-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0002-2018-biopharma-dyslipidemia-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Dyslipidemia | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (<abbr data-original-title=\"cardiovascular\" title=\"\">CV<\/abbr>) disease. With respect to lipid-modifying therapies, the greatest commercial success has come via agents reducing low-density lipoprotein (<abbr data-original-title=\"low-density lipoprotein\" title=\"\">LDL<\/abbr>)-cholesterol, but research and development focusing on triglycerides, high-density lipoprotein (<abbr data-original-title=\"high-density lipoprotein\" title=\"\">HDL<\/abbr>)-cholesterol, and other novel biomarkers is ongoing, with the aim of ultimately providing\u00a0<abbr data-original-title=\"cardiovascular\" title=\"\">CV<\/abbr>\u00a0benefits. During the 2017-2027 forecast period, the dyslipidemia market is expected to have two distinct phases: 1) early contraction owing largely to the genericization of the dominant statin class, and 2) marked growth due to the emergence of novel therapies, including Amgen\u2019s Repatha, Sanofi\/Regeneron Pharmaceuticals\u2019 Praluent, Amarin\u2019s Vascepa, Kowa Pharmaceuticals\u2019 Parmodia (pemafibrate), The Medicines Company\/Alnylam Pharmaceuticals\u2019 inclisiran, Esperion Therapeutics\u2019 bempedoic acid, and AstraZeneca\u2019s Epanova.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What impact will the genericization of AstraZeneca\u2019s Crestor (rosuvastatin)and Merck\u2019s Zetia\/Ezetrol (ezetimibe) and Vytorin\/Inegy (ezetimibe\/simvastatin) have on the dyslipidemia market?<\/li>\n<li>How will\u00a0<abbr data-original-title=\"cardiovascular\" title=\"\">CV<\/abbr>\u00a0outcomes data for the proprotein convertase subtilisin\/kexin type 9 (<abbr data-original-title=\"proprotein convertase subtilisin\/kexin type 9\" title=\"\">PCSK9<\/abbr>) inhibitors and omega-3 fatty acid compounds affect the market?<\/li>\n<li>How will the anticipated launch of Esperion Therapeutics\u2019 orally administered bempedoic acid affect the use of the injectable\u00a0<abbr data-original-title=\"proprotein convertase subtilisin\/kexin type 9\" title=\"\">PCSK9<\/abbr>\u00a0inhibitors? Which products will achieve the greatest use and why?<\/li>\n<li>What impact will the anticipated launch of Kowa\u2019s Parmodia and AstraZeneca\u2019s Epanova have on the management of hypertriglyceridemia?<\/li>\n<\/ul>\n<p><strong>Product Description:<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390542","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-dyslipidemia","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390542\/revisions"}],"predecessor-version":[{"id":576687,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390542\/revisions\/576687"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}